In the last trading session, the stock price of Novavax, Inc. (NASDAQ:NVAX) gained over 14% to close the session at $1.62 on more than normal volume. No specific news accounts for this move. Last month, it commenced a Phase II clinical study evaluating the immunogenicity and safety of its F-protein nanoparticle “RSV F” medication in people at least 60 years old.
The study enrolled 300 subjects, and it will assess the performance of one-dose and two-dose regimens of “RSV F” drug administered without and with aluminum phosphate or the firm’s Matrix-M adjuvant. Top-line report is anticipated in the third quarter of 2017. RSV infection is a notable risk for older people, spreading over 2.5 million Americans annually, resulting in 16,000 deaths and 207,000 hospitalizations. There are presently no RSV drugs commercially available.
Novavax reported the commencement of a Phase II clinical study of its RSV F Vaccine in older adults, 60 years of age and more. The goal of the study is to assess immunogenicity and safety to one and two dose administration plans of the RSV F Vaccine, without and with aluminum phosphate or company’s Matrix-M™ adjuvant, in older subjects.
The study is a randomized, placebo-controlled, observer-blinded trial intended to register up to 300 older patients in the Southern Hemisphere. Subjects are being registered and vaccinated external of the RSV season to best evaluate immunogenicity.
Stanley C. Erck, the President and CEO of Novavax, reported that they consider that a more immunogenic drug in the older subject population should make into an efficacious vaccine. They anticipate the drug from this study to inform the next measures in older adults’ plan, and would ensure they maintain their leadership position in this attractive market opportunity.
Respiratory syncytial virus is a respiratory infectious problem that results in grave infection of the respiratory tract, just like influenza. For some, it may grow in severity, and result in hospitalization or even death. The RSV spread occurs yearly, with an incidence pace of 2.5 million infections yearly in the U.S., RSV is progressively being known as a major cause of mortality and morbidity in the population of as many as 64 million older adults.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of financialstrend.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: